Evidence map›Paper›PMID 40126812›Full record

ArticleOphthalmology and therapy2025

Aqueous Humor Concentrations of Travoprost Free Acid and Residual Drug in Explanted Implants from Patients Administered a Travoprost Intracameral Implant.

Gabriella Szekely, Lilit A Voskanyan, Kerry G Stephens, Long V Doan, Jennifer R Seal, Mohammed K ElMallah, Todd Fjield, David Applegate, Dale W Usner, L Jay Katz and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06582732 (Prospective, Non-Randomized, Open-Label, Single Center Study to Evaluate the Performance of the Travoprost Intraocular Implant), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06582732 phase2completednot on this map

Prospective, Non-Randomized, Open-Label, Single Center Study to Evaluate the Performance of the Travoprost Intraocular Implant

TypeinterventionalSponsorGlaukos CorporationRan2021 to 2023Enrolled210ConditionsGlaucoma, Open-Angle, Ocular HypertensionArmsTravoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6, Travoprost Intracameral Implant exchanged at Month 24, Travoprost intracameral implant exchanged at Month 21
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabriella SzekelyGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
Lilit A VoskanyanOphthalmological Center After Malayan CJSC, 30 Fuchik St, 0048, Yerevan, Armenia.ORCID http://orcid.org/0000-0003-2829-9561
Kerry G StephensGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
Long V DoanGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.ORCID http://orcid.org/0009-0008-0572-2236
Jennifer R SealGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
Mohammed K ElMallahOcala Eye, 4414 SW College Road, Suite 1462, Ocala, FL, 344746, USA.
Todd FjieldGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
David ApplegateGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
Dale W UsnerGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.ORCID http://orcid.org/0000-0002-2799-0652
L Jay KatzGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.
Angela C KotheGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA.ORCID http://orcid.org/0009-0000-7971-5292
Tomas NavratilGlaukos Corporation, One Glaukos Way, Aliso Viejo, CA, 92656, USA. TNavratil@Glaukos.com.ORCID http://orcid.org/0009-0007-3577-3096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo determine the aqueous humor (AH) exposure to travoprost free acid (TFA) and the in vivo elution rate of travoprost over a 24-month period in subjects with open-angle glaucoma administered a travoprost intracameral implant, 75 µg.

methodsIn this prospective, single-center, open-label study, 210 subjects (7 cohorts of 30 subjects each) were administered a travoprost intracameral implant and followed for 3-24 months. At pre-determined timepoints (3, 6, 12, 15, 18, 21, and 24 months), AH was collected, a new implant was administered, and the prior implant removed. AH samples were assayed for TFA concentrations using a validated liquid chromatography-tandem mass spectrometry method. Explants were analyzed for remaining travoprost using a validated high-performance liquid chromatography method.

resultsMean AH concentrations of TFA were 5.0, 3.7, 5.6, 2.0, 2.2, 3.8, and 3.3 ng/mL at 3, 6, 12, 15, 18, 21, and 24 months, respectively, post-administration. Mean percent travoprost remaining in explants was approximately 79%, 70%, 50%, 39%, 35%, 28%, and 16% at 3, 6, 12, 15, 18, 21 and 24 months, respectively, post-administration.

conclusionsConcentrations of TFA in AH through month 24 were above the established efficacious concentration of 0.1 ng/mL for intracameral implants, indicating that adequate TFA levels were achieved to elicit maximal intraocular pressure (IOP)-lowering efficacy, and supported by low levels of IOP in subjects through 24 months. The remaining dose of travoprost in explants at 24 months (i.e., 16%) indicates the potential for efficacious drug delivery beyond 2 years. TRIAL REGISTRATION NUMBER: Clinical Trials.gov Identifier: NCT06582732 (31 August 2024: retrospectively registered).

Indexed as

Aqueous humorGlaucomaIntracameral implantProstaglandin analogTravoprost free acid

Identifiers

PMID40126812
PMCPMC12006621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.